Feliza Mirasol

The ever-increasing complexity of biotherapeutic molecules presents unique analytical challenges for developers.

New biologic modalities, such as cell and gene therapies, pose increasing difficulties in viral clearance testing methods.

The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.

Cell-free expression is promising in preclinical applications, but still presents challenges to scale up for commercial production.